{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:36:28Z","timestamp":1787243788533,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.bbmt.2020.07.036","type":"journal-article","created":{"date-parts":[[2020,8,2]],"date-time":"2020-08-02T10:36:56Z","timestamp":1596364616000},"page":"e280-e285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Chimeric Antigen Receptor T Cell Therapy in Patients with Multiply Relapsed or Refractory Extramedullary Leukemia"],"prefix":"10.1016","volume":"26","author":[{"given":"Jeremy D.","family":"Rubinstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Krupski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen M.","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella M.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine L.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2020.07.036_bib0001","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2020.07.036_bib0002","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.036_bib0003","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.07.036_bib0004","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2020.07.036_bib0005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pcl.2014.09.006","article-title":"Treatment of pediatric acute lymphoblastic leukemia","volume":"62","author":"Cooper","year":"2015","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.bbmt.2020.07.036_bib0006","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMc1704610","article-title":"Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma","volume":"377","author":"Abramson","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.07.036_bib0007","doi-asserted-by":"crossref","first-page":"e28199","DOI":"10.1002\/pbc.28199","article-title":"Chimeric antigen receptor T-cell therapy in patients with neurologic comorbidities","volume":"67","author":"Rubinstein","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"15 suppl","key":"10.1016\/j.bbmt.2020.07.036_bib0008","doi-asserted-by":"crossref","first-page":"10507","DOI":"10.1200\/JCO.2017.35.15_suppl.10507","article-title":"Effect of chimeric antigen receptor-modified T (CAR-T) cells on responses in children with non-CNS extramedullary relapse of CD19+ acute lymphoblastic leukemia (ALL)","volume":"35","author":"Talekar","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.07.036_bib0009","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1182\/blood.V126.23.3769.3769","article-title":"Efficient trafficking of chimeric antigen receptor (CAR)-modified T cells to CSF and induction of durable CNS remissions in children with CNS\/combined relapsed\/refractory ALL","volume":"126","author":"Rheingold","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.036_bib0010","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.07.036_bib0011","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2005-12-011809","volume":"108","author":"Matloub","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.036_bib0012","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.036_bib0013","doi-asserted-by":"crossref","first-page":"e26928","DOI":"10.1002\/pbc.26928","article-title":"Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: a Children's Oncology Group study","volume":"65","author":"Barredo","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2020.07.036_bib0014","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2019.237230","article-title":"Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433 [e-pub ahead of print]","author":"Lew","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2020.07.036_bib0015","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.036_bib0016","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bjh.15195","article-title":"Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB","volume":"181","author":"Li","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2020.07.036_bib0017","doi-asserted-by":"crossref","first-page":"6327","DOI":"10.2147\/OTT.S164430","article-title":"Extramedullary relapse of acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation treated by CAR T-cell therapy: a case report","volume":"11","author":"Wang","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.bbmt.2020.07.036_bib0018","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13045-018-0572-x","article-title":"A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia","volume":"11","author":"Weng","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bbmt.2020.07.036_bib0019","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/s41409-019-0778-8","article-title":"Successful chimeric antigen receptor T cells therapy in extramedullary relapses of acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation","volume":"55","author":"Zhang","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.036_bib0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.07.036_bib0021","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bbmt.2020.07.036_bib0022","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"issue":"15 suppl","key":"10.1016\/j.bbmt.2020.07.036_bib0023","doi-asserted-by":"crossref","first-page":"10511","DOI":"10.1200\/JCO.2020.38.15_suppl.10511","article-title":"CD19-targeted chimeric antigen receptor (CAR) T cells in CNS relapsed acute lymphoblastic leukemia (ALL)","volume":"38","author":"Newman","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.07.036_bib0024","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1200\/JCO.2005.03.3373","article-title":"Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a Pediatric Oncology Group study","volume":"24","author":"Barredo","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.07.036_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108107","article-title":"Outcome of central nervous system relapses in childhood acute lymphoblastic leukaemia\u2013prospective open cohort analyses of the ALLR3 trial","volume":"9","author":"Masurekar","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bbmt.2020.07.036_bib0026","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41409-018-0259-5","article-title":"Hematopoietic stem cell transplantation for isolated extramedullary relapse of acute lymphoblastic leukemia in children","volume":"54","author":"Gabelli","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.036_bib0027","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/sj.leu.2405037","volume":"22","author":"Eapen","year":"2008","journal-title":"Leukemia"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120304687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120304687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:13:23Z","timestamp":1761059603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879120304687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1083879120304687"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.07.036","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric Antigen Receptor T Cell Therapy in Patients with Multiply Relapsed or Refractory Extramedullary Leukemia","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.07.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}